Megan Othus

MedicineNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

0.968Author DataRank

Indexed papers

5in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae009

Top 44%

0.418DataRank

Top 44%6 citations

Sandip Pravin Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher, Elad Sharon +2 more

Papers

Driven by 82 papers — median percentile 53. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437

N/A

6.5DataRank · unranked

846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002990

N/A

4.8DataRank · unranked

160 citations

Megan Othus, Sandip Pravin Patel, Chris Ryan, Ashish Sangal, Benjamin Powers +15 more

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

Cancer Cell(2021)10.1016/j.ccell.2021.07.023

N/A

3.9DataRank · unranked

135 citations

Sixue Liu, Zhentao Yang, Alain P. Algazi, Shirley H. Lomeli, Yan Wang +16 more

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2182

N/A

3.8DataRank · unranked

125 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia

Blood Advances(2022)10.1182/bloodadvances.2022008216

N/A

1.8DataRank · unranked

72 citations

Anna Moseley, Kristen M. O’Dwyer, Brent L. Wood, Jae H. Park, Matthew J. Wieduwilt +12 more

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9501

N/A

1.3DataRank · unranked

18 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella +15 more

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia

Haematologica(2023)10.3324/haematol.2023.283520

N/A

1.1DataRank · unranked

35 citations

Jake Higgins, Hassan Nasif, Megan Othus, Lan Beppu, Thomas H. Smith +8 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141

N/A

0.700DataRank · unranked

105 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers

Cancer(2024)10.1002/cncr.35200

N/A

0.612DataRank · unranked

12 citations

James Moon, Christopher D. Lao, Bartosz Chmielowski, Kari Kendra, Karl D. Lewis +12 more

Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1073

N/A

0.524DataRank · unranked

32 citations

Megan Othus, Sandip Pravin Patel, Young Kwang Chae, Kathy D. Miller, Rashmi Chugh +8 more

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia

Haematologica(2022)10.3324/haematol.2022.281585

N/A

0.505DataRank · unranked

28 citations

Jacob A. Wilson, Min Fang, Brenda M. Sandmaier, Eduardo Rodríguez‐Arbolí, Brent L. Wood +4 more

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2293

N/A

0.505DataRank · unranked

28 citations

Megan Othus, Young Kwang Chae, Michael J. Dennis, Sarah Gordon, David G. Mutch +9 more

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009074

N/A

0.503DataRank · unranked

12 citations

Megan Othus, Young Kwang Chae, Tridu R. Huynh, Benjamin Tan, Timothy M. Kuzel +9 more

SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer

Cancer(2024)10.1002/cncr.35243

N/A

0.496DataRank · unranked

15 citations

Elizabeth Guadarrama, Young Kwang Chae, Michael J. Dennis, Benjamin Powers, Chih‐Yi Liao +9 more

Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia

JCO Oncology Practice(2020)10.1200/jop.19.00133

N/A

0.477DataRank · unranked

23 citations

Megan Othus, Guillermo Garcia‐Manero, Min Fang, Jerald P. Radich, David A. Rizzieri +24 more

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

Haematologica(2022)10.3324/haematol.2022.281631

N/A

0.470DataRank · unranked

22 citations

Megan Othus, Corentin Orvain, Lucas C. Zarling, Brenda M. Sandmaier, Filippo Milano +7 more

Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae009

Top 44%

0.418DataRank

Top 44%6 citations

Sandip Pravin Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher, Elad Sharon +2 more

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2148212

N/A

0.406DataRank · unranked

14 citations

Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby +15 more

A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations)

Blood(2021)10.1182/blood-2021-145529

N/A

0.396DataRank · unranked

13 citations

Anna Moseley, Kristen O'Dwyer, Brent Wood, Jae H Park, Matthew Wieduwilt +12 more

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review

Cancers(2023)10.3390/cancers15092561

N/A

0.396DataRank · unranked

13 citations

Arish Noor, Mahati Paravathaneni, Ibrahim Yassine, Sandra J. Lee, Megan Othus +7 more

First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae297

Top 47%

0.385DataRank

Top 47%8 citations

Sandip Pravin Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher, Elad Sharon +2 more

Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission

Bone Marrow Transplantation(2022)10.1038/s41409-022-01909-x

N/A

0.385DataRank · unranked

12 citations

Brenda M. Sandmaier, Megan Othus, Corentin Orvain, Eduardo Rodríguez‐Arbolí, Masumi Ueda +5 more

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009128

N/A

0.380DataRank · unranked

9 citations

Megan Othus, Sandip Pravin Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan +11 more

SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0606

N/A

0.373DataRank · unranked

11 citations

Megan Othus, Sandip Pravin Patel, Kelly J. Wilkinson, Emily M. Whitman-Purves, Jayanthi Lea +21 more

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia

medRxiv(2023)10.1101/2023.03.26.23287367

N/A

0.330DataRank · unranked

8 citations

Jake Higgins, Hassan Nasif, Megan Othus, Lan Beppu, Thomas H. Smith +8 more

Avoiding Delays in Reporting Time-to-Event Randomized Trials: Calendar Backstops and Other Approaches

Journal of Clinical Oncology(2024)10.1200/jco.24.00025

N/A

0.312DataRank · unranked

7 citations

Boris Freidlin, Edward L. Korn, Megan Othus

Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma

npj Precision Oncology(2025)10.1038/s41698-024-00798-1

N/A

0.303DataRank · unranked

5 citations

Eleanor Cano-Linson, Young Kwang Chae, Shiruyeh Schokrpur, Christopher D. Lao, Benjamin Powers +13 more

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1957

N/A

0.292DataRank · unranked

6 citations

Lucy Corthell, Sandip Pravin Patel, Robert P. Edwards, Jennifer Scalici, Hye Sung Kim +10 more

Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts

Leukemia(2024)10.1038/s41375-024-02143-8

N/A

0.292DataRank · unranked

6 citations

Andrew H. Wei, Sumithra J. Mandrekar, Ing Soo Tiong, Chong Chyn Chua, Tse‐Chieh Teh +24 more

Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility

Haematologica(2020)10.3324/haematol.2020.254938

N/A

0.269DataRank · unranked

5 citations

Megan Othus, Sarah Mirahsani, Kelda M. Gardner, Carole Shaw, Anna B. Halpern +6 more

SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4179

N/A

0.269DataRank · unranked

5 citations

Edward Mayerson, E. Gabriela Chiorean, Earle F. Burgess, Elizabeth M. Swisher, Carl M. Gay +9 more

Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-011760

N/A

0.245DataRank · unranked

4 citations

Jillian Fisher, Young Kwang Chae, Luisa M. Solis Soto, Anup Kasi, Bhavana Konda +27 more

Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients

Biomarker Research(2023)10.1186/s40364-023-00461-0

N/A

0.241DataRank · unranked

4 citations

Xing Hua, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, Harry P. Erba +14 more

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

Cancer Communications(2025)10.1002/cac2.70020

N/A

0.208DataRank · unranked

3 citations

Megan Othus, Sandip Pravin Patel, Raid Aljumaily, Khine Z. Win, Tanya Pejovic +12 more

S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps9585

N/A

0.208DataRank · unranked

3 citations

Megan Othus, James Moon, Michael T. Tetzlaff, Elizabeth I. Buchbinder, Vernon K. Sondak +9 more

Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps7567

N/A

0.208DataRank · unranked

3 citations

Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael Fisch +9 more

AML Risk Stratification Models Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Research Square(2020)10.21203/rs.3.rs-24023/v1

N/A

0.208DataRank · unranked

3 citations

Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, I-Ming L. Chen +17 more

Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024

Blood Cancer Journal(2025)10.1038/s41408-025-01294-w

N/A

0.175DataRank · unranked

2 citations

Alexis Berridge-Green, Megan Othus, Jerald P. Radich, Anjali S. Advani, Harry P. Erba +2 more

Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials

Clinical Trials(2025)10.1177/17407745241304065

N/A

0.165DataRank · unranked

2 citations

Michael LeBlanc, Boris Freidlin, Rory M. Shallis, Amer M. Zeidan, David A. Sallman +4 more

Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network

Haematologica(2023)10.3324/haematol.2023.282733

N/A

0.165DataRank · unranked

2 citations

Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, Harry P. Erba +10 more

Metabolic Syndrome and Risks of Breast Cancer Outcomes for Luminal, Triple-Negative, and HER2-Overexpressing Subtypes

Cancer Epidemiology Biomarkers & Prevention(2024)10.1158/1055-9965.epi-24-1167

Top 70%

0.165DataRank

Top 70%2 citations

Megan Othus, Kathleen E. Malone, Hannah M. Linden, Mei‐Tzu C. Tang, Christopher I. Li +1 more

Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1881512

N/A

0.165DataRank · unranked

2 citations

Megan Othus, Guillermo Garcia‐Manero, Frederick R. Appelbaum, Harry P. Erba, Roland B. Walter +1 more

S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps10090

N/A

0.104DataRank · unranked

1 citations

Megan Othus, James Moon, Michael T. Tetzlaff, Elizabeth I. Buchbinder, Vernon K. Sondak +8 more

Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)

Therapeutic Advances in Medical Oncology(2024)10.1177/17588359241293401

N/A

0.104DataRank · unranked

1 citations

Megan Othus, Sandip Pravin Patel, David E. Gerber, Tawee Tanvetyanon, Hye Sung Kim +10 more

Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2504

N/A

0.104DataRank · unranked

1 citations

Sandip Pravin Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher, Elad Sharon +2 more

Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10039

N/A

0.104DataRank · unranked

1 citations

Megan Othus, Adil Daud, Janice M. Mehnert, Thach‐Giao Truong, Robert M. Conry +15 more

Modulators of relapse risk in adults allografted for acute myeloid leukemia in measurable residual disease-positive remission

Bone Marrow Transplantation(2025)10.1038/s41409-025-02533-1

N/A

0.104DataRank · unranked

1 citations

Megan Othus, Brenda M. Sandmaier, Chris Davis, Ryan Basom, Roland B. Walter +1 more

Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multicenter Basket Trial Analysis (NCI/SWOG S1609)

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-2900

N/A

0.104DataRank · unranked

1 citations

S Solomon, Sandip Pravin Patel, Zouina Sarfraz, Megan Othus, Young Kwang Chae +2 more

Granulomatous and sarcoid-like immune related adverse events (irAEs) in melanoma patients following CTLA4 blockade adjuvant therapy: An analysis of 1670 high-risk patients.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9582

N/A

0.104DataRank · unranked

1 citations

Ibrahim Yassine, Sandra J. Lee, Megan Othus, James Moon, John M. Kirkwood +5 more

Data from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

10.1158/1078-0432.c.6530837.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

1073P Quality of life (QOL) endpoints from the phase III intergroup S1404 adjuvant melanoma trial

Annals of Oncology(2021)10.1016/j.annonc.2021.08.1458

N/A

0DataRank · unranked

0 citations

Joseph M. Unger, Megan Othus, Amy K. Darke, Ahmad A. Tarhini, John M. Kirkwood +5 more

Relationship Between Pretransplantation Nutritional Status and Outcome in Adults with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.09.023

N/A

0DataRank · unranked

15 citations

Mariia Byelykh, Megan Othus, Brenda M. Sandmaier, Gary Schoch, Chris Davis +3 more

Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

Bone Marrow Transplantation(2022)10.1038/s41409-022-01794-4

N/A

0DataRank · unranked

11 citations

Corentin Orvain, Megan Othus, Roland B. Walter, Eduardo Rodríguez‐Arbolí

Clinical trials: design, endpoints and interpretation of outcomes

Bone Marrow Transplantation(2022)10.1038/s41409-021-01542-0

N/A

0DataRank · unranked

12 citations

Mei-Jie Zhang, Robert Peter Gale, Megan Othus

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2131416

N/A

0DataRank · unranked

0 citations

Ian Thomas, Xu Wang, Cono Ariti, Priyanka Mehta, Mia Sydenham +11 more

1469 A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic disease

(2022)10.1136/jitc-2022-sitc2022.1469

N/A

0DataRank · unranked

0 citations

Megan Othus, Young Kwang Chae, Michael J. Dennis, Sarah Gordon, David G. Mutch +7 more

Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia

Scientific Reports(2020)10.1038/s41598-020-62345-9

N/A

0DataRank · unranked

4 citations

Shannon McDonough, Cheryl L. Willman, Eric R. Koegle, John E. Godwin, Stephen H. Petersdorf +8 more

Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia

Journal of Clinical Oncology(2023)10.1200/jco.22.01114

N/A

0DataRank · unranked

30 citations

Jenny L. Smith, Megan Othus, Benjamin J. Huang, Yicheng Wang, Rhonda E. Ries +14 more

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5517

N/A

0DataRank · unranked

4 citations

Megan Othus, Sandip Pravin Patel, Robert P. Edwards, Jennifer Scalici, Liam Il‐Young Chung +8 more

Data from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

(2023)10.1158/1078-0432.c.6530837

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16330

N/A

0DataRank · unranked

0 citations

Elizabeth Guadarrama, Young Kwang Chae, Chih‐Yi Liao, Anup Kasi, Grace R. Tarabay +12 more

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11516

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan +10 more

Reply to Z.R. McCaw et al

Journal of Clinical Oncology(2023)10.1200/jco.23.00986

N/A

0DataRank · unranked

0 citations

Megan Othus, Yicheng Wang, Todd A. Alonzo, Soheil Meshinchi, Jason E. Farrar

Signal detection in real‐world data and confirmation in clinical trials: Diabetes as a case study for a conversation worth having

Cancer(2023)10.1002/cncr.34939

N/A

0DataRank · unranked

0 citations

Megan Othus, Zoe Quandt, Elad Sharon

Measurable residual disease as predictor of post–day +100 relapses after allografting in adult AML

Blood Advances(2024)10.1182/bloodadvances.2024013214

N/A

0DataRank · unranked

19 citations

Megan Othus, Eduardo Rodríguez‐Arbolí, Corentin Orvain, Filippo Milano, Brenda M. Sandmaier +5 more

Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Cancers(2020)10.3390/cancers12092339

N/A

0DataRank · unranked

41 citations

Brenda M. Sandmaier, Megan Othus, Raffaele Palmieri, Noa Granot, Evandro D. Bezerra +10 more

Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia

Leukemia(2024)10.1038/s41375-024-02172-3

N/A

0DataRank · unranked

12 citations

Megan Othus, Corentin Orvain, Eduardo Rodríguez‐Arbolí, Filippo Milano, Brenda M. Sandmaier +6 more

Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up

Value in Health(2020)10.1016/j.jval.2020.02.015

N/A

0DataRank · unranked

14 citations

Aasthaa Bansal, Harry P. Erba, Scott D. Ramsey, Megan Othus

Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)

Leukemia(2024)10.1038/s41375-024-02378-5

N/A

0DataRank · unranked

12 citations

Megan Othus, Sylvie Freeman, Francesco Buccisano, Lok Lam Ngai, Ian Thomas +11 more

Time independent factors that predict relapse in adults with acute myeloid leukemia

Blood Cancer Journal(2024)10.1038/s41408-023-00954-z

N/A

0DataRank · unranked

8 citations

Megan Othus, Carole Shaw, Kathryn Russell, Anna B. Halpern, Jacob Appelbaum +5 more

Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML

American Journal of Hematology(2024)10.1002/ajh.27259

N/A

0DataRank · unranked

8 citations

Naveed Ali, Megan Othus, Eduardo Rodríguez‐Arbolí, Filippo Milano, Calvin M. Le +5 more

Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Adult Acute Myeloid Leukemia: Outcomes and Prognostic Factors

Transplantation and Cellular Therapy(2024)10.1016/j.jtct.2024.06.019

N/A

0DataRank · unranked

7 citations

Megan Othus, Corentin Orvain, Naveed Ali, Filippo Milano, Chris Davis +6 more

Relationship between morphologic remission with or without hematologic recovery and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia

Bone Marrow Transplantation(2024)10.1038/s41409-024-02407-y

N/A

0DataRank · unranked

2 citations

Domitilla Baccon, Naveed Ali, Eduardo Rodríguez‐Arbolí, Corentin Orvain, Filippo Milano +5 more

Reverse Selection Designs for Accommodating Multiple Control Arms

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1282

N/A

0DataRank · unranked

0 citations

Megan Othus, Michael LeBlanc, Michael C. Wu, Sarah Samorodnitsky

Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report

eJHaem(2024)10.1002/jha2.1041

N/A

0DataRank · unranked

0 citations

Megan Othus, Chenwei Lin, Melinda A. Biernacki, Marie Bleakley, Thomas R. Chauncey +20 more

Relationship Between Age, Conditioning Intensity, and Outcome After Allografting in Adults Age ≥60 Years with AML

Research Square(2024)10.21203/rs.3.rs-5220097/v1

N/A

0DataRank · unranked

0 citations

Brenda M. Sandmaier, Megan Othus, Naveed Ali, Eduardo Rodríguez‐Arbolí, Corentin Orvain +5 more

Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML

Bone Marrow Transplantation(2025)10.1038/s41409-025-02516-2

N/A

0DataRank · unranked

5 citations

Brenda M. Sandmaier, Megan Othus, Naveed Ali, Eduardo Rodríguez‐Arbolí, Corentin Orvain +5 more

CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia

Cancers(2025)10.3390/cancers17142323

N/A

0DataRank · unranked

1 citations

Megan Othus, Anne-Chloe Olix, Kate A. Markey, Derek L. Stirewalt, Laura Connelly‐Smith +4 more

Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203

Leukemia(2025)10.1038/s41375-024-02512-3

N/A

0DataRank · unranked

0 citations

Guillermo Garcia‐Manero, Frederick R. Appelbaum, Harry P. Erba, Eliana Dietrich, Suravi Raychaudhuri +4 more

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy

Blood Neoplasia(2025)10.1016/j.bneo.2025.100129

N/A

0DataRank · unranked

0 citations

Megan Othus, Mary‐Elizabeth M. Percival, Guillermo Garcia‐Manero, Frederick R. Appelbaum, Harry P. Erba +2 more

Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10059

N/A

0DataRank · unranked

0 citations

Megan Othus, Benjamin Newell Voorhies, Kari Kendra, Shaker R. Dakhil, Amy Harker-Murray +6 more

Megan Othus

Indexed papers

Top data-sharing exemplar

Papers